Probiotic Strain Combination for Staphylococcus Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Staphylococcus infections, particularly those induced by methicillin-resistant Staphylococcus aureus (MRSA), pose a significant challenge due to widespread antibiotic resistance, leading to ineffective treatments and difficult prophylaxis, especially in hospital settings where the spread of infection is a major concern.
Innovation Solution
A pharmaceutical preparation comprising a combination of specific viable α-Streptococcus and Lactobacillus strains, such as Streptococcus sanguis II, Streptococcus mitis, Streptococcus oralis, Streptococcus lactis, Lactobacillus rhamnosus, Lactobacillus plantarum, and their variants, which work synergistically to inhibit, repress, or kill Staphylococcus strains, creating a physical barrier and modulating the immune system to prevent infection and spread.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic medicaments are used for treatment of Staphylococcus infections, then treatment effectiveness is initially improved, but antibiotic resistance develops leading to treatment failure
Solution Approach 1:
The patent utilizes the harmful effect of Staphylococcus bacteria by employing bacteriocins produced by Streptococcus strains that specifically target and eliminate Staphylococcus, including MRSA strains that have developed resistance to conventional antibiotics. This converts the problem of antibiotic resistance into a solution by using a different biological mechanism (bacteriocin-mediated killing) that bypasses traditional antibiotic resistance pathways.
Solution Approach 2:
The patent changes the fundamental parameter of antimicrobial action from antibiotic-mediated inhibition to bacteriocin-mediated cell lysis. By using bacteriocins that form pores in bacterial cell membranes and cause osmotic lysis, the treatment mechanism fundamentally differs from antibiotic action, thereby overcoming resistance developed against conventional antibiotics.
2Reliability
If single-strain probiotics are used for prophylaxis, then some protective effect is achieved, but the effect is insufficient against MRSA
Solution Approach 1:
The patent combines multiple Streptococcus strains (including S. salivarius, S. mitis, S. oralis) with specific Lactobacillus strains (including L. rhamnosus, L. plantarum, L. fermentum) into a synergistic probiotic preparation. This multi-strain combination creates a more robust and comprehensive protective effect against MRSA compared to single-strain probiotics, leveraging the complementary mechanisms of different bacterial strains.
Solution Approach 2:
The patent creates a composite probiotic system where multiple bacterial strains work together to provide enhanced protection. The combination includes strains that produce different types of bacteriocins, compete for adhesion sites, and modulate the immune system through diverse mechanisms, creating a composite biological defense system that is more effective than individual strains alone.
3Reliability
If broad-spectrum antibiotics are used to treat Staphylococcus infections, then infection treatment is achieved, but normal flora is disrupted and resistance spreads
Solution Approach 1:
The patent converts the problem of disrupted normal flora into a benefit by using probiotic strains that actively restore and enhance the natural bacterial community. The Streptococcus and Lactobacillus strains colonize the mucosal surfaces, compete with pathogenic bacteria for resources and adhesion sites, and restore the natural protective barrier, thereby benefiting from what would otherwise be a harmful disruption.
Solution Approach 2:
The probiotic preparation enables the host's own microbiota to provide protection against Staphylococcus infections. By introducing beneficial strains that produce bacteriocins and compete with pathogens, the body's natural defenses are enhanced and sustained without requiring continuous antibiotic intervention, allowing the system to protect itself against future infections.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of these strains effectively reduces or eliminates harmful Staphylococcus strains on mucosal membranes and skin, providing a prophylactic and therapeutic effect against Staphylococcus-induced infections, including MRSA, by creating a physical barrier and enhancing the immune response, with a synergistic effect that surpasses the individual effects of the strains when used alone.
Implementation Method 1
The combined strains give rise to an unforeseeably advantageous effect in that they kill or inhibit growth of Staphylococcus strains, in particular of MRSA
Implementation Method 2
occupy the epithelial cells, the matrix and the mucosal membranes and the skin creating a kind of physical barrier
Implementation Method 3
modulating the immune system to prevent infection and spread
Data Source
AI summary
A pharmaceutical preparation for prophylaxis against and treatment of Staphylococcus induced infections or condi-tions in humans and animals, is disclosed, wherein it comprises a combination of a) one or more viable α-Streptococcus strains chosen from the group consisting of the Streptococcus sanguis JI strains having the accession numbers NCTMB 40104, NCTMB 40105, NCIMB 40106, and NCIMB 40873, the Streptococcus mitis strains having the accession numbers NCIMB 40107, and NCIMB 40874, the Streptococcus oralis strains having the accession numbers NCIMB 40875 and NCIMB 40876, the Streptococcus lactis strain LIA having the accession number NCIMB 40157, and one or more variants thereof having the same or essentially similar effect; and b) one or more viable Lactobacillus strains chosen from the group consisting of the Lactobacillus rhamnosus strain LB2 I having the accession number NCIMB 40564, the Lactobacillus plantamm strain LB3 having the accession number DSM 17852, and the Lactobacillus plantarwn strain LB7 having the accession number DSM 1 7853, and one or more variants thereof having the same or essentially similar effect; in at least one pharmaceutically acceptable medium in which said strains maintain their viability, as well as a kit for and a method of prophylaxis and treatment of Staphylococcus induced infections and conditions, and use.